Earlier this year, antivenom manufacturer Sanofi-Pasteur announced it was no longer able to produce antivenom for snake bite. However, "the reality is that for the vast majority of Africa's snake bite victims, the loss of Sanofi's antivenom will mean little, if anything at all," argues David Williams, head of the Australian Venom Research Unit at the University of Melbourne.
This is because the product simply never reached them in the first place.